Our top 5 headlines include a target date for a cholesterol-lowering drug, long-term dermatology data, and an expanded dosing label for geographic atrophy.
This approval by the FDA of Evolus’s 2 new hyaluronic acid gels provides an additional set of options for dermatologists in the aesthetic products market.